On the other hand, ILC2s were reported to amplify the antitumor effect of PD-1 blockades by activating tumor-specific T cells in an orthotopic murine model of pancreatic tumors [52], emphasizing the requirement for characterization of intra-tumoral ILC populations [33]. The gene discussed is CCL27; the disease is neoplasm.